Any current/future new fundraising through debt or equity?

The company has utilized about INR 200 crores of bank finance this year, resulting in some visible finance costs. This debt has already been reduced to approximately INR 150 crores, with expectations to minimize it further by the end of the current quarter. The company has been essentially a zero-debt company for the last 2 years prior to this utilization. There is no explicit mention of plans for new fundraising through either debt or equity in the provided excerpts. The company is focusing on cautious capital allocation, prioritizing capacity creation and maintenance aligned with medium-term

Any current/future capex/capital investment/strategic investment?

New formulation and technical plant at Dahej site is operational and expected to improve performance in FY '27. Sotanala facility: formulation plant to start Q1 of FY '27, technical plant expected in 2027. Capex focused on capacity creation and maintenance aligned with medium-term growth priorities. Backward integration planned selectively for specialist products to gain cost advantage and improve profitability. Investment decisions based on ROCE and ROE; non-essential capex being frozen to rationalize business. Strategy includes expanding technical capacity selectively; building new technical

Future growth expectations in sales/revenue/volumes?

The company targets a sustainable growth of 8% to 10% over the next 2 to 3 years. Growth for FY '27 is expected to be cautiously positive, with recovery signs starting in Q1. At least 5 new product launches are planned in Q1 of FY '27, including specialty and proprietary products. The focus is on premiumization and specialty products, which command higher farmer investment and improve margins. Volume-led growth is anticipated, with B2B segment growing approximately 15% and B2C segment around 3-4%. The company expects improved profitability with better product mix, operational efficiency, and w

Future growth expectations in earnings/operating earnings/profits/EPS?

Company targets **low double-digit EBITDA margins** for the full year, with a cautious improvement expected beyond that (Pages 16-17). EBITDA might be flat short-term but expected to increase through rationalizing non-essential capex and working capital efficiency (Page 17). Focus on **premium and specialty products** to drive better margins and profitability growth (Pages 12-13, 17). Sales growth forecasted at around **8%-10% over the next 2-3 years**, reflecting a clear growth revival roadmap (Page 6). Margins expected to be better than top-line growth but Q4 may see muted profitability due

IN US

Sale is live|00:00:00left today

Insecticides India LtdQ4 FY27Fertilizers & Agrochemicals

Insecticides India Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→The company targets a sustainable growth of 8% to 10% over the next 2 to 3 years.
→Growth for FY '27 is expected to be cautiously positive, with recovery signs starting in Q1.
→At least 5 new product launches are planned in Q1 of FY '27, including specialty and proprietary products.
→The focus is on premiumization and specialty products, which command higher farmer investment and improve margins.
→Volume-led growth is anticipated, with B2B segment growing approximately 15% and B2C segment around 3-4%.
→The company expects improved profitability with better product mix, operational efficiency, and working capital management.
→Exports are gaining traction with 180+ registrations across 22 countries, supporting long-term revenue growth.
→Overall, the company is focusing on quality growth, portfolio expansion, and strategic global collaborations to drive future sales.

Margin guidance

Category 3

→Company targets **low double-digit EBITDA margins** for the full year, with a cautious improvement expected beyond that (Pages 16-17).
→EBITDA might be flat short-term but expected to increase through rationalizing non-essential capex and working capital efficiency (Page 17).
→Focus on **premium and specialty products** to drive better margins and profitability growth (Pages 12-13, 17).
→Sales growth forecasted at around **8%-10% over the next 2-3 years**, reflecting a clear growth revival roadmap (Page 6).
→Margins expected to be better than top-line growth but Q4 may see muted profitability due to seasonality and market conditions (Page 15).
→FY 2027 expected to be a **good year cautiously** with signs of recovery starting Q1 (Page 15).
→Company emphasizes **discipline and long-term franchise strength** over short-term margin optics (Page 6).
→Continuous focus on building **Maharatna and Focus Maharatna category products** expected to be revenue and profit engines (Page 17).

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has utilized about INR 200 crores of bank finance this year, resulting in some visible finance costs.
→This debt has already been reduced to approximately INR 150 crores, with expectations to minimize it further by the end of the current quarter.
→The company has been essentially a zero-debt company for the last 2 years prior to this utilization.
→There is no explicit mention of plans for new fundraising through either debt or equity in the provided excerpts.
→The company is focusing on cautious capital allocation, prioritizing capacity creation and maintenance aligned with medium-term growth priorities.
→Overall, there is no indication of any immediate or planned new fundraising through debt or equity at present.

Order book

The transcript does not explicitly mention specific details about current or expected orderbook/pending orders. However, some related points include: - Focus on selective sales in Q4 with faster conversion on identified geographies, crops, and accounts to protect top line and market share. - Emphasis on strict pricing floors and order-wise profitability tracking in B2B sales. - Continued traction from new product launches contributing to order flow and demand. - International business is gradually gaining traction with registrations underway in markets like Latin America and Australia. - The company aims to build momentum in specialty and premium products, suggesting a positive outlook on incoming orders. - Tight controls on inventory and working capital hint at active order management and fulfillment focus. No explicit quantitative orderbook or pending orders were disclosed in the call.

Capex plans

Yes

→New formulation and technical plant at Dahej site is operational and expected to improve performance in FY '27.
→Sotanala facility: formulation plant to start Q1 of FY '27, technical plant expected in 2027.
→Capex focused on capacity creation and maintenance aligned with medium-term growth priorities.
→Backward integration planned selectively for specialist products to gain cost advantage and improve profitability.
→Investment decisions based on ROCE and ROE; non-essential capex being frozen to rationalize business.
→Strategy includes expanding technical capacity selectively; building new technical plants typically takes around 2-3 years.
→Plans to double investment in ICS Plots (Integrated Crop Solutions) to deepen farmer connect and brand equity.
→Emphasis on disciplined capital allocation with focus on increasing capital efficiency and improving organizational revenue, ROCE, and ROE by 6-7% over three years.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Insecticides India Ltd

Rev 4Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio